Stockscreener 앱 받기
32.86
2.02%
0.65
시간 외 거래:
32.86
전일 마감가:
$32.21
열려 있는:
$32.61
하루 거래량:
672.40K
Relative Volume:
0.77
시가총액:
$3.70B
수익:
$14.09M
순이익/손실:
$-176.94M
주가수익비율:
-15.28
EPS:
-2.15
순현금흐름:
$-141.24M
1주 성능:
+11.92%
1개월 성능:
+30.97%
6개월 성능:
+116.75%
1년 성능:
+85.23%
1일 변동 폭
$31.69
$33.28
1주일 범위
$29.44
$34.62
52주 변동 폭
$14.06
$34.62
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
명칭
Newamsterdam Pharma Company Nv
전화
35 206 2971
주소
GOOIMEER 2-35, NARRDEN
NAMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
32.86 | 3.63B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-25 | 개시 | Wells Fargo | Overweight |
| 2025-07-17 | 개시 | Goldman | Neutral |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-06-10 | 개시 | Stifel | Buy |
| 2025-06-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-15 | 개시 | TD Cowen | Buy |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-18 | 개시 | Guggenheim | Buy |
| 2024-01-16 | 개시 | Piper Sandler | Overweight |
| 2023-10-30 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
Knights of Columbus Asset Advisors LLC Invests $595,000 in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
NewAmsterdam Pharma Company N.V. (NAMS) Soars 5.9%: Is Further Upside Left in the Stock? - Yahoo Finance
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Up 8.8%Here's Why - MarketBeat
Newamsterdam Pharma stock hits 52-week high at 31.96 USD By Investing.com - Investing.com Nigeria
NewAmsterdam Pharma Co. Hits New 52-Week High of USD 31.81 - Markets Mojo
Is NewAmsterdam Pharma Company NV a good long term investmentRSI Overbought/Oversold & Exceptional Profit Trading - earlytimes.in
Newamsterdam Pharma stock hits 52-week high at 31.96 USD - Investing.com India
Will NewAmsterdam Pharma Company N.V. (KH6) stock beat Nasdaq index returnsQuarterly Earnings Summary & Target Return Focused Stock Picks - newser.com
Institutional scanner results for NewAmsterdam Pharma Company N.V.Portfolio Risk Report & Entry Point Confirmation Alerts - newser.com
How NewAmsterdam Pharma Company N.V. stock performs in weak economyWeekly Stock Summary & Smart Money Movement Alerts - newser.com
Published on: 2025-10-05 03:30:23 - newser.com
NewAmsterdam Pharma Company N.V. Equity Warrant stock retracement – recovery analysisStock Surge & Real-Time Market Sentiment Alerts - newser.com
NewAmsterdam Pharma Co. NV Hits New 52-Week High at $29.66 - Markets Mojo
Exit strategy if you’re trapped in NewAmsterdam Pharma Company N.V.July 2025 Setups & Verified Technical Signals - newser.com
Can you recover from losses in NewAmsterdam Pharma Company N.V.Quarterly Performance Summary & Daily Market Momentum Tracking - newser.com
How NewAmsterdam Pharma Company N.V. (KH6) stock moves on employment dataJuly 2025 Volume & Free Technical Confirmation Trade Alerts - newser.com
Published on: 2025-10-02 23:50:02 - newser.com
Using data tools to time your NewAmsterdam Pharma Company N.V. exitEarnings Growth Report & Risk Adjusted Buy/Sell Alerts - newser.com
Why NewAmsterdam Pharma Company N.V. Equity Warrant stock attracts global investorsTrade Signal Summary & Growth Oriented Trading Recommendations - newser.com
Is NewAmsterdam Pharma Company N.V. stock reversal real or fakeJuly 2025 Trends & Stock Portfolio Risk Management - newser.com
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results - ADVFN
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - ADVFN
NewAmsterdam Pharma (NASDAQ:NAMS) Reaches New 12-Month HighHere's What Happened - MarketBeat
Published on: 2025-10-01 08:11:23 - newser.com
NewAmsterdam Pharma Stock Hits Day High with 8.41% Surge - Markets Mojo
NewAmsterdam Pharma Soars 9.15% to Hit Intraday High of $26.75 - Markets Mojo
What drives NewAmsterdam Pharma Company NV Equity Warrant stock price - earlytimes.in
Is this a good reentry point in NewAmsterdam Pharma Company N.V.2025 Biggest Moves & AI Driven Stock Reports - newser.com
NewAmsterdam Pharma Co. NV Hits New 52-Week High of $28.61 - Markets Mojo
Is Vakrangee Limited Stock Risky in the Current Market EnvironmentPrice Support Zones & Low Cost Wealth Investment - earlytimes.in
What analysts say about NewAmsterdam Pharma Company NV KH6 stockMorning Star Patterns & Invest Now – Opportunity Window Closing - earlytimes.in
NewAmsterdam Pharma Company NV KH6 Stock Analysis and ForecastSupport and Resistance Levels & Low Entry Investment Portfolio - earlytimes.in
Top chart patterns to watch in NewAmsterdam Pharma Company N.V. Equity Warrant2025 Price Momentum & Expert Approved Trade Ideas - newser.com
What drives NewAmsterdam Pharma Company NV KH6 stock priceInstitutional Holding Changes & Affordable Growth Investments - Early Times
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Sets New 1-Year HighHere's What Happened - MarketBeat
Newamsterdam Pharma stock hits 52-week high at 27.4 USD By Investing.com - Investing.com Canada
Newamsterdam Pharma stock hits 52-week high at 27.4 USD - Investing.com
What analysts say about NewAmsterdam Pharma Company NV stockFibonacci Retracement Levels & Free Daily Investment Newsletter Subscription - Early Times
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum - GlobeNewswire
Non-Statin Medicine Developer NewAmsterdam Pharma to Present Latest CVD Research at Stifel Forum - Stock Titan
Newamsterdam Pharma Company Nv (NAMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.05%
4.71%
자본화:
|
볼륨(24시간):